In their series seed prime financing round, Nanochon, a biotech orthopaedic device startup situated in Washington, DC, raised $4 million.
Investors
- The University of Virginia Licensing
- Cultivate (MD)
- Alumni Venture Group
- Mountain State Capital
- Ventures Group
Use of funds
The business plans to enhance research and development operations, broaden its patent portfolio, hire more people, and launch its first in-person clinical trials in the US in 2024 using the money raised.
About Nanochon
Nanochon is a biotech and medical device firm dedicated on creating cutting-edge orthopedic treatments. Ben Holmes is the CEO and co-founder of the company. ChondrograftTM is a minimally invasive implant that enables rapid mobility and weight bearing, reducing the amount of time needed for recovery.
This year, the business will launch a phase I study in the US for its exclusive knee implant, ChondrograftTM. To avoid the need for expensive and time-consuming total knee replacements, the gadget simply needs minimally invasive surgery to regenerate broken bone and cartilage.
